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Abstract
Background: Volume-based parameters, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG),
on F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) are useful for predicting treatment response
in nonsmall cell lung cancer (NSCLC). We aimed to examine intra- and inter-operator reproducibility to measure the
MTV and TLG, and to estimate their dependency on the uptake time.
Methods: Fifty NSCLC patients underwent preoperative FDG-PET. After an injection of FDG, the whole body
was scanned twice: at the early phase (61.4 ± 2.8 min) and delayed phase (117.7 ± 1.6 min). Two operators
independently defined the tumor boundary using three different delineation methods: (1) the absolute SUV
threshold method (MTVp and TLGp; p = 2.0, 2.5, 3.0, 3.5), (2) the fixed% SUVmax threshold method (MTVq% and
TLGq%; q = 35, 40, 45), and (3) the adaptive region-growing method (MTVARG and TLGARG). Parameters were
compared between operators and between phases.
Results: Both the intra- and inter-operator reproducibility were high for all parameters using any method
(intra-class correlation > 0.99 each). MTV3.0 and MTV3.5 resulted in a significant increase from the early to
delayed phase (P < 0.05 for both), whereas MTV2.0 and MTV2.5 neither increased nor decreased (P = n.s.). All of
the MTVq% values significantly decreased over time (P < 0.01), whereas MTVARG and TLG with any delineation
method increased significantly (P < 0.05).
Conclusions: High reproducibility of MTV and TLG was obtained by all of the methods used. MTV2.0 and
MTV2.5 were the least sensitive to uptake time, and may be good alternatives when we compare images
acquired with different uptake times, although applying constant uptake time is important for volume
measurement.
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Background
Positron emission tomography (PET) using F-18 fluoro-
deoxyglucose (FDG) has been an essential diagnostic
tool in oncology [1–3]. FDG-PET generates functional
images that contribute to clinical diagnoses and treat-
ment planning complementarily with anatomical modal-
ities such as computed tomography (CT) and magnetic
resonance imaging (MRI). PET is also characterized by
high quantitative performance [4–6]. In most clinical set-
tings, FDG-PET images were assessed semi-quantitatively
using the standardized uptake value (SUV), which com-
monly represents the radioactivity concentration per unit
volume of tissue normalized to the injected dosage and
body weight [7]. The maximum of the SUV (SUVmax)
within the tumor has been used most frequently to ex-
press the intensity of FDG uptake in the tumor because of
its simplicity and high reproducibility [8–12]. However,
the SUVmax has several problems. Because the SUVmax
represents just a single voxel (normally < 0.1 ml) and not
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the entire tumor metabolism, it is sensitive to statistical
noise of the image [13]. In recent years, the use of the
SUVpeak has been preferred [13]. The definition of SUV-
peak remains to be standardized, but usually calculated by
averaging SUV within a 1-ml sphere (12 mm in diameter)
around the voxel showing highest intensity voxel. The
SUVpeak is less sensitive to image noise but suffers from
the same problem as SUVmax still reflects a small part of
the tumor [14, 15].
In this context, the metabolic tumor volume (MTV)
and total lesion glycolysis (TLG) has been recently
used as indices of the whole tumor FDG uptake. The
MTV is defined as the volume of tumor determined
on an FDG-PET image using a certain threshold.
Once MTV is determined, the SUVmean can be
defined as the averaged SUV within MTV. TLG is
the product of the MTV and the SUVmean. These
indicators reflect the activity of the glucose metabol-
ism in the entire tumor. The clinical usefulness of
these indicators (e.g., prognosis and treatment re-
sponse) has been demonstrated in many cancers
such as lung [16, 17], head-and-neck [18–20], and
gynecological cancer [21, 22].
Calculating the MTV and TLG requires tumor
contouring on the PET image. Many methods have
been reported to determine the contour [23–31], and
among them, manual contouring, the absolute SUV
threshold method, and relative SUV threshold
methods have been used widely. With the manual
contouring method, the tumor boundary is deter-
mined based on an operator’s visual inspection. This
operator-dependent method suffers from reproduci-
bility and is affected by the window level and color
scale. It also takes a long time to apply this manual
operation to all of the images containing tumors.
Other methods have thus been developed to reduce
the effects from display conditions or operators.
There is no doubt that the SUVmax has high intra-
and inter-operator reproducibility, but the reproduci-
bility of MTV and TLG still needs to be assessed. In
the present study, we examined intra-operator repro-
ducibility (i.e., the same operator analyzes the same
image twice) and inter-operator reproducibility (i.e.,
two operators analyze the same image independently).
In addition, considering possible effects of uptake
time after the FDG administration on the MTV and
TLG, we acquired PET images twice after a single in-
jection (at 60 and 120 min), and we compared the
MTV and TLG between these images. We applied
different delineation methods that are widely used.
Thus, in this study, we aimed to evaluate (1) intra-
operator reproducibility, (2) inter-operator reproduci-




All procedures performed in studies involving human
participants were in accordance with the ethical stan-
dards of the institutional and/or national research com-
mittee and with the 1964 Helsinki declaration and its
later amendments or comparable ethical standards. The
institutional ethics committee of Hokkaido Cancer Cen-
ter approved this retrospective study. Informed consent
was waived from individual participants in the retro-
spective study according to the committee. Patient re-
cords/information was anonymized and de-identified
prior to analysis. From our hospital information system,
we found a total of 52 patients who underwent FDG-
PET for an examination of lung nodules before treat-
ment at the National Hospital Organization Hokkaido
Cancer Center between December 2010 and March
2012. One patient was suspected of having metastatic
lung tumor from breast cancer, and another patient did
not complete the scanning because of severe pain. Thus,
we included 50 patients (27 males; age, 70.2 ± 10.1 years
old) whose lung nodules were visualized by FDG-PET
and whose nodule(s) were pathologically confirmed as
non-small cell lung cancer (NSCLC). The patient char-
acteristics are shown in Table 1. Briefly, body weight was
56.0 ± 9.0 kg (range 39–87 kg); tumor existed in the
upper lobe (N = 30), the middle lobe (N = 4), or the
lower lobe (N = 16) of the lung; pathological diagnosis
was adenocarcinoma (N = 28), squamous cell carcinoma
(N = 14), or others (N = 8); cancer stage was IA (N = 12),
IB (N = 6), IIA (N = 10), IIB (N = 3), IIIA (N = 8), IIIB
(N = 5) or IV (N = 6) based on the American Joint
Committee on Cancer (AJCC) TNM system.
Image acquisition and reconstruction
All of the clinical FDG-PET studies were performed
with an Eminence SET-3000G PET scanner (Shimadzu,
Kyoto, Japan). All of the patients fasted for at least
6 h before the injection of FDG (224 ± 54 MBq,
range 142–294 MBq; 4.0 ± 0.9 MBq/kg, range 2.5–
6.4 MBq/kg). The blood glucose level was 100 ±
19 mg/dl. The images were scanned twice for each
study: early scanning at 61.4 ± 2.8 min (range 58–
67 min) and delayed scanning at 117.7 ± 1.6 min
(range 114–121 min). The transaxial field of view
was 512 mm in diameter. Three-dimensional emis-
sion scanning was performed in a continuous bed-
movement manner (0.8–0.9 mm/s). Transmission
scanning was performed with a 137Cs external source
to correct for attenuation.
Images were reconstructed with a block-iterative
algorithm named ‘dynamic row-action maximum likeli-
hood algorithm (DRAMA),’ modified from the row-
action maximum likelihood algorithm (RAMLA) [32].
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Table 1 Patient characteristics
Case Age range (y) Weight (kg) Dosage (MBq) Dosage/Weight (MBq/kg) Tumor location Pathologya TNM classification Stage
1 80–89 43.3 142 3.3 L S3 Ade pT1aN0M0 IA
2 70–79 56.5 166 2.9 R S6 SCC cT3N2M0 IIIA
3 80–89 50.0 239 4.8 L S1 + 2 Ade cT2aN0M0 IB
4 60–69 46.3 162 3.5 L S8 SCC pT2aN0M0 IB
5 80–89 52.6 283 5.4 R S7 Ade pT2aN2M0 IB
6 60–69 63.0 164 2.6 R S6 SCC pT1aN0M0 IA
7 70–79 48.6 146 3.0 R S3 Ade pT1bN0M0 IA
8 70–79 46.5 144 3.1 R S2 Ade pT2aN1M0 IIA
9 70–79 72.4 292 4.0 R S5 SCC pT1aN0M0 IA
10 70–79 47.4 242 5.1 R S1 Ade cT4N2M0 IIIB
11 30–39 40.7 147 3.6 R S8 MEDC pT1bN0M0 IA
12 70–79 45.9 294 6.4 L S9 Ade pT1bN0M0 IA
13 50–59 50.0 239 4.8 R S1 Ade pT1aN0M0 IA
14 60–69 65.7 276 4.2 L S1 + 2 SCC cT4N3M1b IV
15 50–59 60.7 294 4.8 L S5 Ade pT2aN1M1b IV
16 60–69 52.1 243 4.7 R S2 SCC cT4N3M0 IIIB
17 80–89 56.2 236 4.2 R S2 Ade pT1aN0M0 IA
18 70–79 57.4 145 2.5 R S7 LCNEC pT2aN2M0 IB
19 70–79 78.4 242 3.1 L S1 + 2 SCC pT1bN0M0 IA
20 50–59 60.6 242 4.0 R S1 Ade pT1bN2M0 IIIA
21 60–69 67.2 243 3.6 L S3 Ade pT3N1M0 IIIA
22 80–89 48.5 240 5.0 R S10 Ade pT2bN0M0 IIA
23 60–69 64.7 243 3.8 L S10 SCC pT3N0M0 IIB
24 70–79 51.4 242 4.7 L S9 Ade pT2bN0M0 IIA
25 60–69 54.8 292 5.3 R S3 Ade pT2aN0M0 IIA
26 60–69 45.9 224 4.9 L S1 + 2 Ade pT4N0M0 IIIA
27 80–89 62.7 242 3.9 L S1 + 2 SCC cT3N0M0 IIB
28 70–79 55.4 146 2.6 R S4 Ade cT2bN1M1b IV
29 60–69 59.4 239 4.0 R S2 Ade pT2bN0M0 IIA
30 70–79 53.0 145 2.7 L S10 PC pT2aN1M0 IIB
31 70–79 55.3 237 4.3 R S1 PC pT1aN0M0 IA
32 70–79 50.7 146 2.9 L S4 Ade pT1aN3M0 IIIB
33 60–69 68.8 274 4.0 R S5 Ade cT2aN2M1 IV
34 60–69 57.2 245 4.3 R S1 SCC cT3N2M0 IIIA
35 70–79 45.6 242 5.3 R S1 Ade pT1aN0M0 IA
36 80–89 54.6 274 5.0 L S1 + 2 Ade pT3N1M0 IIIA
37 70–79 46.6 146 3.1 R S3 Ade pT1aN2M0 IIIA
38 80–89 51.4 292 5.7 R S10 LCNEC pT2aN0M0 IIA
39 80–89 74.8 273 3.6 R S4 Ade pT2aN0M0 IIA
40 60–69 51.9 166 3.2 R S3 Ade cT2aN0M1b IV
41 70–79 40.8 164 4.0 R S3 Ade pT2aN0M0 IB
42 50–59 45.2 166 3.7 L S3 SCC cT4N2M0 IIIB
43 50–59 61.4 266 4.3 R S7 PC pT2aN2M1 IV
44 50–59 72.2 290 4.0 L S10 SCC cT2bN3M0 IIIB
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The iteration and filter cycle values for DRAMA were 1
and 128, respectively. The reconstructed image had a
spatial resolution of 8.4 mm full-width at half-maximum
and a matrix size of 128 × 128 with the voxel size 4.0 ×
4.0 × 2.0 mm. A smoothing filter was not applied.
Image processing
A total of 100 FDG-PET datasets (two datasets, i.e., early
and delayed images, from 50 patients) were processed to
delineate the tumor by two operators (Fig. 1). Operator-
1 (T.K.) is an experienced radiologic technologist of
nuclear medicine, and Operator-2 (K.H.) is an experi-
enced nuclear medicine physician. Both Operator-1 and
Operator-2 independently defined the tumor boundary
two times with an interval of 30 days or longer (i.e., a
total of 4-time measurements). Operator-2 defined the
tumor boundary once without viewing the results re-
ported by Operator-1, and vice versa. Hereinafter, we
use these three abbreviations: Op1Ob1 representing the
first observation from operator-1, Op1Ob2 representing
the second observation from operator-1, Op2Ob1
representing the first observation from Operator-2, and
Op2Ob2 representing the second observation from
Operator-2. The volume-of-interest (VOI) was defined
by manually drawing polygonal regions of interest
(ROIs) to enclose the entire tumor with enough margins
on every slice where the tumor was seen. During the
ROI definition, the PET images were displayed using a
rainbow color bar with a fixed window level of SUV 0–
4. Physiological uptake was carefully avoided. Neither
lymph nodes nor distant metastatic lesions were investi-
gated in this study. All of the ROIs were combined to
generate a three-dimensional VOI.
In this study, we used the following three delineation
methods. (1) The absolute SUV threshold method, which
is a procedure of defining the area of the tumor as a re-
gion with a certain value higher than predetermined
threshold, such as an SUV of 2.5 or 3.0. (2) The fixed%
SUVmax threshold method, which is a procedure for de-
fining the area of the tumor as a region with a higher SUV
than a certain percentage of the SUVmax within the
tumor (40–50 %, commonly). (3) The adaptive region-
growing method (ARG), which is a relatively new method
[26]. The ARG is essentially a region-growing method that
examines neighboring voxels of the current region and de-
termines whether the neighbor voxels should be added to
the in-tumor region. If {a neighbor voxel} ≥ {mean of
current region} × {arbitrary threshold}, the voxel is added
to the region. There is a sharp volume increase point
when the threshold (%) varies from 100 to 0 %, and the
tumor region is determined by this border point. With this
method, the area of the tumor can be extracted automatic-
ally by the setting of the highest voxel in the tumor. Be-
cause the ARG method uses a new procedure, there are
still few studies using this method.
The tumor volume was automatically determined
within the VOI using different methods: MTVp, MTVq%,
and MTVARG. MTVp is the MTV determined using the
absolute SUV threshold method, where p = 2.0, 2.5, 3.0,
or 3.5. MTVq% is the MTV determined using the fixed%
SUVmax threshold method, where q = 35, 40, or 45 %.
Table 1 Patient characteristics (Continued)
45 60–69 62.4 166 2.7 R S1 LCNEC pT2aN0M0 IIA
46 60–69 54.3 274 5.1 R S8 Ade pT1aN0M0 IA
47 70–79 59.4 164 2.8 R S3 SCC pT2aN0M0 IB
48 60–69 65.6 239 3.6 L S3 Ade pT2aN1M0 IIA
49 70–79 61.9 292 4.7 R S3 SCC pT1bN2M0 IIIA
50 60–69 60.9 290 4.8 R S6 ASCC pT1aN1M0 IIA





Fig. 1 a Regions of interest defined by Operator-1 (solid line) and
Operator-2 (dashed line). b Corresponding CT slice
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Values of p and q were chosen based on their frequency
of appearance in literature [13]. MTVARG is the MTV
determined using ARG method.
TLG was defined as the product of the corresponding
MTV and SUVmean values within the tumor boundary.
The SUVmax was also recorded, which represented the
voxel showing the highest SUV in the VOI. The SUV
was calculated as [tissue radioactivity concentration (Bq/
ml)] × [body weight (g)] /[injected radioactivity (Bq)].
For all the image analysis including manual ROI draw-
ing, mathematical delineation, and parameter calcula-
tion, we used an in-house software package, composed
with Visual Studio 2010 (Microsoft Corporation,
Redmond, Washington, USA) and C# language.
Statistical analysis
Values are expressed as the mean ± SD. The free stat-
istical package R version 3.2.5 (R Project, http://
cran.r-project.org) was used for all statistical analyses.
A paired t-test was used if the values could be con-
sidered paired. The method of Holm was used to ad-
just the P-values for multiple comparisons. The intra-
class correlation (ICC) was used to evaluate intra-
and inter-operator reproducibility [33]. Intra-operator
reproducibility was estimated by 2 combinations: 1)
Op1Ob1 vs. Op1Ob2, and 2) Op2Ob1 vs. Op2Ob2.
Inter-operator reproducibility can be estimated by 4
combinations: 1) Op1Ob1 vs. Op2Ob1, 2) Op1Ob1 vs.
Op2Ob2, 3) Op1Ob2 vs. Op2Ob1, and 4) Op1Ob2 vs.
Op2Ob2. P-values <0.05 were considered as significant.
Results
Reproducibility
Both intra- and inter-operator reproducibility were ex-
tremely high at the early phase (Table 2) and the delayed
phase (Table 3). The ICC between the first versus second
measurement by Operator-1 or Operator-2 was > 0.99 for
any parameters. Similarly, the ICC between Operator-1
versus Operator-2 was > 0.99 for any parameters. Among
the parameters, no difference was observed in SUVmax,
MTVARG or TLGARG in any case (i.e., perfect match).
Comparisons between methods revealed that most of the
MTVq% values were lower than those of MTVp or
MTVARG.
Parameter changes from the early phase to the delayed
phase
Parameter changes from early to delayed phases are
summarized in Table 4. The SUVmax increased in 49 of
the 50 (98 %) cases at the delayed phase compared
to the early phase (early, 9.1 ± 4.9; delayed, 11.1 ± 6.0;
P < 0.0001). The MTV changes depended on the
Table 2 Intra- and inter-operator reproducibility of PET parameters at the early phase
Op1Ob1 Op1Ob2 Op2Ob1 Op2Ob2 ICC intra-operator
reproducibility
ICC inter-operator reproducibility












SUVmax 9.1 ± 4.9 9.1 ± 4.9 9.1 ± 4.9 9.1 ± 4.9 1 1 1 1 1 1
MTV2.0 55.0 ± 100.6 54.9 ± 102.5 52.8 ± 96.6 52.8 ± 96.4 >0.999 >0.999 0.997 0.997 0.997 0.997
MTV2.5 39.4 ± 72.1 39.3 ± 72.5 39.1 ± 70.7 38.9 ± 70.4 >0.999 >0.999 >0.999 >0.999 >0.999 0.999
MTV3.0 29.7 ± 51.7 29.7 ± 51.6 29.8 ± 51.3 29.7 ± 51.1 >0.999 >0.999 >0.999 >0.999 >0.999 >0.999
MTV3.5 23.4 ± 38.2 23.4 ± 38.1 23.5 ± 38.0 23.4 ± 37.8 >0.999 >0.999 >0.999 >0.999 >0.999 >0.999
MTV35% 25.0 ± 31.9 24.3 ± 31.7 23.7 ± 31.5 23.7 ± 31.5 0.998 >0.999 0.997 0.992 0.997 0.997
MTV40% 19.2 ± 22.9 18.9 ± 22.8 18.6 ± 22.7 18.6 ± 22.7 0.998 >0.999 0.998 0.996 0.998 0.998
MTV45% 15.0 ± 17.1 14.9 ± 17.1 14.8 ± 16.9 14.8 ± 16.9 >0.999 1 >0.999 0.999 >0.999 >0.999
MTVARG 43.0 ± 62.1 43.0 ± 62.1 43.0 ± 62.1 43.0 ± 62.1 1 1 1 1 1 1
TLG2.0 225.2 ± 365.2 224.9 ± 369.0 220.4 ± 354.5 220.0 ± 353.5 >0.999 >0.999 0.999 0.999 0.999 0.999
TLG2.5 190.4 ± 304.6 190.1 ± 305.5 189.8 ± 300.1 189.2 ± 298.9 >0.999 >0.999 >0.999 >0.999 >0.999 >0.999
TLG3.0 164.0 ± 253.7 163.7 ± 253.4 164.4 ± 251.8 163.8 ± 250.7 >0.999 >0.999 >0.999 >0.999 >0.999 >0.999
TLG3.5 143.6 ± 215.0. 143.4 ± 214.7 144.1 ± 213.7 143.6 ± 212.9 >0.999 >0.999 >0.999 >0.999 >0.999 >0.999
TLG35% 132.7 ± 179.5 131.8 ± 179.7 131.4 ± 179.2 131.3 ± 179.1 >0.999 >0.999 >0.999 >0.999 >0.999 >0.999
TLG40% 112.8 ± 148.3 112.3 ± 148.3 112.2 ± 147.7 112.1 ± 147.7 >0.999 >0.999 >0.999 >0.999 >0.999 >0.999
TLG45% 96.2 ± 124.7 96.0 ± 124.7 96.0 ± 123.9 96.0 ± 123.9 >0.999 1 >0.999 >0.999 >0.999 >0.999
TLGARG 196.4 ± 290.0 196.4 ± 290.0 196.4 ± 290.0 196.4 ± 290.0 1 1 1 1 1 1
ICC intra-class correlation, Op1Ob1 Operator-1's first observation, Op1Ob2 Operator-1's second observation, Op2Ob1 Operator-2's first observation, Op2Ob2
Operator-2's second observation
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delineation methods. Among them, the MTV2.0 and
MTV2.5 neither increased nor decreased from the early
phase to the delayed phase with the averaged delayed-to-
early ratios of 1.02 and 1.06, respectively (P = nonsignifi-
cant for both). The use of a higher threshold (i.e., MTV3.0
and MTV3.5) led to a significant increase from the early to
the delayed phase (P < 0.05 for both). All of the MTVq%
values (i.e., MTV35%, MTV40%, and MTV45%) significantly
decreased (P < 0.001), whereas the MTVARG values signifi-
cantly increased (P < 0.05) (Fig. 2). In contrast, the TLG
obtained by any of the delineation methods was signifi-
cantly increased at the delayed phase (Fig. 3).
Discussion
In this study of volume-based parameters on FDG-PET
for NSCLC, we found high intra- and inter-operator
reproducibility for all parameters (ICC >0.99 each). We
also evaluated the time sensitivity of the parameters by
comparing early-phase images with delayed-phase images.
Whereas the SUVmax increased significantly at the
delayed phase, the MTV changes depended on the delin-
eation method, and the TLG obtained by any of the delin-
eation methods was significantly increased at the delayed
phase (P < 0.05). Among the parameters examined, only
MTV2.0 and MTV2.5 were the parameters that neither
increased nor decreased at the delayed phase.
Table 3 Intra- and inter-operator reproducibility of PET parameters at the delayed phase
Op1Ob1 Op1Ob2 Op2Ob1 Op2Ob2 ICC intra-operator
reproducibility
ICC inter-operator reproducibility












SUVmax 11.1 ± 6.0 11.1 ± 6.0 11.1 ± 6.0 11.1 ± 6.0 1 1 1 1 1 1
MTV2.0 56.2 ± 107.2 56.2 ± 107.9 54.1 ± 101.0 54.7 ± 101.8 >0.999 >0.999 0.996 0.995 0.993 0.994
MTV2.5 41.9 ± 79.6 41.8 ± 79.3 41.6 ± 77.6 41.9 ± 78.0 >0.999 >0.999 0.999 0.998 0.997 0.997
MTV3.0 33.1 ± 60.9 33.0 ± 60.3 33.5 ± 60.6 33.3 ± 60.3 >0.999 >0.999 >0.999 0.998 0.998 0.998
MTV3.5 27.3 ± 48.2 27.2 ± 47.7 27.5 ± 47.8 27.7 ± 48.1 >0.999 >0.999 >0.999 0.998 0.998 0.998
MTV35% 21.0 ± 29.0 20.9 ± 28.7 20.5 ± 28.7 20.6 ± 28.8 >0.999 >0.999 0.998 0.997 0.996 0.997
MTV40% 16.6 ± 21.2 16.5 ± 21.0 16.4 ± 21.0 16.5 ± 21.1 >0.999 >0.999 0.999 0.999 0.998 0.999
MTV45% 13.2 ± 15.7 13.1 ± 15.5 13.1 ± 15.5 13.1 ± 15.6 >0.999 >0.999 >0.999 >0.999 >0.999 >0.999
MTVARG 50.4 ± 76.2 50.4 ± 76.2 50.4 ± 76.2 50.4 ± 76.2 1 1 1 1 1 1
TLG2.0 259.1 ± 431.3 258.6 ± 430.8 254.4 ± 414.8 256.8 ± 418.8 >0.999 >0.999 0.998 0.997 0.996 0.997
TLG2.5 227.2 ± 372.8 226.4 ± 370.5 226.4 ± 365.4 228.2 ± 368.4 >0.999 >0.999 >0.999 0.998 0.998 0.998
TLG3.0 203.4 ± 325.8 202.6 ± 322.9 205.4 ± 324.8 203.8 ± 322.0 >0.999 >0.999 >0.999 0.999 0.998 0.998
TLG3.5 184.5 ± 288.8 183.8 ± 286.3 184.9 ± 285.5 186.5 ± 288.3 >0.999 >0.999 >0.999 0.999 0.998 0.999
TLG35% 145.2 ± 206.5 144.5 ± 204.8 144.3 ± 204.7 145.4 ± 206.3 >0.999 >0.999 >0.999 >0.999 0.999 0.999
TLG40% 125.8 ± 173.3 125.2 ± 171.9 125.0 ± 171.2 126.0 ± 172.6 >0.999 >0.999 >0.999 >0.999 0.999 >0.999
TLG45% 108.1 ± 145.3 107.6 ± 144.1 107.3 ± 143.2 108.1 ± 144.3 >0.999 >0.999 >0.999 >0.999 >0.999 >0.999
TLGARG 249.4 ± 383.5 249.4 ± 383.5 249.4 ± 383.5 249.4 ± 383.5 1 1 1 1 1 1
ICC intra-class correlation, Op1Ob1 Operator-1's first observation, Op1Ob2 Operator-1's second observation, Op2Ob1 Operator-2's first observation, Op2Ob2
Operator-2's second observation
Table 4 The parameter changes from the early phase to the
delayed phase
Early Phase (E) Delayed Phase (D) D/E (mean) P-value
n = 50
SUVmax 9.1 ± 4.9 11.1 ± 6.0 1.22 <0.0001
MTV2.0 55.0 ± 100.6 56.2 ± 107.2 1.02 NS
MTV2.5 39.4 ± 72.1 41.9 ± 79.6 1.06 NS
MTV3.0 29.7 ± 51.7 33.1 ± 60.9 1.11 <0.05
MTV3.5 23.4 ± 38.2 27.3 ± 48.2 1.17 <0.05
MTV35% 25.0 ± 31.9 21.0 ± 29.0 0.84 <0.001
MTV40% 19.2 ± 22.9 16.6 ± 21.2 0.86 <0.001
MTV45% 15.0 ± 17.1 13.2 ± 15.7 0.88 <0.001
MTVARG 43.0 ± 62.1 50.4 ± 76.2 1.17 <0.05
TLG2.0 225.2 ± 365.2 259.1 ± 431.3 1.15 <0.01
TLG2.5 190.4 ± 304.6 227.2 ± 372.8 1.19 <0.001
TLG3.0 164.0 ± 253.7 203.4 ± 325.8 1.24 <0.001
TLG3.5 143.6 ± 215.0. 184.5 ± 288.8 1.28 <0.001
TLG35% 132.7 ± 179.5 145.2 ± 206.5 1.09 <0.05
TLG40% 112.8 ± 148.3 125.8 ± 173.3 1.12 <0.01
TLG45% 96.2 ± 124.7 108.1 ± 145.3 1.12 <0.01
TLGARG 196.4 ± 290.0 249.4 ± 383.5 1.27 <0.001
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Intra- and inter-operator reproducibility
In case that the tumor exists without adjacent non-
tumor uptakes (i.e., physiological or inflammatory), the
semi-automated methods we employed in this study
should not cause variability of measurement theoretic-
ally. However, it is not uncommon that the tumor is so
close to mediastinum that the manual ROIs include
parts of blood pool or lymph nodes. In such cases, even
semi-automated methods are expected to cause some
variation if the threshold is lower than the non-tumor
uptake. In this study, we observed both the intra- and
inter-operator reproducibility were high for all parame-
ters. Although we observed minimal differences in some
cases between the two measurements when relatively
low threshold (absolute or fixed% SUVmax) was used, as
expected, we consider that the high ICCs may allow use
of the methods. Shah et al. reported high inter-operator
reproducibility of MTV and TLG using a fixed%
SUVmax threshold method that showed the ICCs be-
tween two measurements by one operator as > 0.98 for
MTV and > 0.99 for TLG [33]. Frings et al. demonstrated
high repeatability in the same examination of the two
measurement within 1 week using FDG or 18F-
fluorothymidine (FLT) [34]. Our results are in line
with these previous reports. The difference we ob-
served may be small enough for clinical use.
In contrast, using the ARG method, the twice-
measurements of the tumor volume completely agreed,
because this method delineates the tumor boundary
without requiring a manual ROI [26]. Our results are
consistent with this report in terms of high inter-
operator reproducibility. However, as a shortcoming, this
method does not always successfully determine the
tumor boundary, especially when images are noisy or
the boundaries are indistinct (or ambiguous). Conduct-
ing phantom experiments, Li et al. reported that the
Fig. 2 Bland-Altman plots showing the parameter changes between the early phase and delayed phase of the MTV, which is a general threshold
value. MTV2.5 had few parameter changes (a), MTV40% decreased (b), and MTVARG increased (c) from the early phase to the delayed phase
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ARG method generates a slightly larger volume than the
actual tumor volume, and that the degree of volume
overestimation depended on the source-to-background
ratio. They thus recommended that use of the ARG
method should be followed by an appropriate volume
correction.
Early and delayed scans
MTV is the volume where the tumor cells are actively
metabolizing glucose. Note that MTV is not an uptake
quantification. The volume should not change within a
few hours but should be stable if there is no significant
tumor growth. In fact, however, many methods of MTV
measurement resulted in significant volume changes
from the early phase to the delayed phase except for
MTV2.0 and MTV2.5. In contrast, TLG is the arbitrary
amount of glucose metabolized during the period from
injection to image acquisition. Thus, TLG may change
over time theoretically. In the present study, we investi-
gated malignant tumors only; thus, the FDG inflow is
thought to continue even 1 h after the injection, result-
ing in higher uptake at 2 h [35, 36]. Among the MTVs
measured by different methods, MTV2.0 and MTV2.5
neither increased nor decreased from the early to the de-
layed phase, probably because the increase in tumor up-
take and the decrease in the surrounding background
uptake (e.g., in a lung field or mediastinum blood pool)
would have cancelled each other out. Conversely, the
MTV35%, MTV40%, and MTV45% values all significantly
decreased because the increase in the SUVmax raised
the delineation cut-off value. MTVARG increased due to
the increase in the tumor-to-background ratio at the de-
layed phase. TLG by all delineation methods significantly
increased; this is likely due to the increase in the
Fig. 3 Bland-Altman plots showing the parameter changes between the early phase and the delayed phase of TLG, which is general threshold
value. Unlike Fig. 2, TLG obtained by any delineation method was increased at the delayed phase (a-c)
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SUVmean within the region. Our present report is the
first to show parameter changes from the early to de-
layed phases.
PERCIST, the guideline for PET response criteria in
solid tumors, requires that a PET scan for baseline
should be obtained at 50–70 min after injection, and the
follow-up scan should be obtained within 15 min of the
baseline scan [13]. In our observation, almost all param-
eters changed from the early phase to the delayed phase,
which further supported the importance of time strict-
ness. However, it is not always easy to perform scanning
under such a strict protocol in many clinical conditions.
In particular, when we try to carry out a retrospective
analysis, the uptake time restriction will exclude a num-
ber of scans. We suggest that use of MTV2.0 or MTV2.5
could be an alternative way to minimize the influence of
uptake time variability.
It should be noted that MTV2.5 is the most commonly
used method thus far, and is known to be well correlated
with patient outcomes of various cancers [27, 28, 37].
For instance, Kao et al. showed that MTV2.5 was the
most appropriate parameter for predicting recurrence
after radiotherapy for pharyngeal cancer patients in
comparison with MTV3.0, MTV40%, and MTV50% [28].
Based on our present findings, MTV3.0 or MTV with
higher thresholds may not be appropriate if the uptake
time is not constant. Another reason to avoid higher
thresholds is that a significant number of cases showed
zero volume using such thresholds.
MTVq%has also been frequently used. MTVq% is actually
better at tumor volume measurements in a phantom
study because it is relatively resistant to partial volume ef-
fects. However, this method may appropriately work when
the tumor has intermediate SUVmax (e.g., 5–10) but may
under- or over-estimate the volume in cases of consider-
ably high or low SUVmax of tumor, respectively. There-
fore, it is difficult to fix relative threshold (%) in studies
investigating a large number of patients. Considering the
difficulty in fixing an absolute or relative SUV threshold,
the ARG procedure is an attractive method that does not
require manual interaction. Although the ARG method
did achieve very good intra- and inter-operator reproduci-
bility in the present study, its high sensitivity to uptake
time necessitated further improvement. TLG seems to ex-
tract more information of PET than MTV does, because
TLG is an uptake quantification whereas MTV is just a
volume. Superiority of TLG to MTV for treatment re-
sponse of lung cancer has been reported recently [38, 39].
As mentioned above, however, the TLG obtained by any
of the delineation methods was significantly increased at
the delayed phase. Therefore, when we use datasets ac-
quired with a fluctuating uptake time, we recommend that
MTV2.5 should be chosen as the best volume-based par-
ameter among many MTVs and TLGs.
The limitations of this study include the following. We
investigated reproducibility and parameter changes by
uptake time, but we did not report the prognostic value.
Future studies will be needed to combine the present
findings and prognostic information. In addition, it is
necessary to study cancers other than lung cancer. For
lung cancer, a manual ROI was defined relatively easily
because the tumor existed in the lung showing low FDG
uptake. Reproducibility may be affected in fields that
have higher physiological uptake, such as the head-and-
neck and pelvis.
Conclusions
The MTV and TLG of primary lesions of 50 NSCLC pa-
tients were measured with different tumor delineation
methods and different uptake times. We found that both
the intra- and inter-operator reproducibility were ex-
tremely high for all parameters. Most of the MTV values
and all of the TLG values were significantly affected by
the uptake time. Among the various parameters studied,
MTV2.0 and MTV2.5 were the least sensitive to the up-
take time, and may be good alternatives when we com-
pare images acquired with different uptake times,
although applying constant uptake time is important for
volume measurement.
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